Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer.

PD-(L)1 inhibitors have improved prognosis of non-small-cell lung cancer (NSCLC), but can also cause immune-related adverse events (irAEs) that complicate management. We analyzed NSCLC patients receiving PD-(L)1 inhibitors from 2012 to 2020 in a German academic center. IrAE showed comparable frequencies in stage IV (198/894 or 22%) Approximately one-fourth of immunotherapy-treated NSCLC patients develop irAEs, most of which necessitate treatment suspension and steroids. Despite more frequent occurrence with PD-L1 positive tumors, lower NLR, and better ECOG PS, irAEs are independently associated with longer survival, especially when affecting the skin. Lethality is below 1%.

Informations de copyright

Copyright © 2021 Daniello, Elshiaty, Bozorgmehr, Kuon, Kazdal, Schindler, Shah, Volckmar, Lusky, Diekmann, Liersch, Faehling, Muley, Kriegsmann, Benesova, Stenzinger, Thomas and Christopoulos.

Déclaration de conflit d'intérêts

FB: research funding from BMS and travel grants from BMS and MSD. JK: research funding from AstraZeneca and Celgene. DK: advisory board and speaker’s honoraria from AstraZeneca, BMS, Pfizer. RS: research funding from BMS. KB: research funding from Novartis and Abbvie, speaker’s honoraria/advisory board/travel grants from Abbvie, BMS, Gilead/Galapagos, Janssen, Lilly, Medac, MSD, Mundipharma, Novartis, Pfizer, Roche, UCB. AS: advisory board honoraria from BMS, AstraZeneca, ThermoFisher, Novartis, speaker’s honoraria from BMS, Illumina, AstraZeneca, Novartis, ThermoFisher, MSD, Roche, and research funding from Chugai. MT: advisory board honoraria from Novartis, Lilly, BMS, MSD, Roche, Celgene, Takeda, AbbVie, Boehringer, speaker’s honoraria from Lilly, MSD, Takeda, research funding from AstraZeneca, BMS, Celgene, Novartis, Roche and travel grants from BMS, MSD, Novartis, Boehringer. PC: research funding from AstraZeneca, Novartis, Roche, Takeda, and advisory board/lecture fees from AstraZeneca, Boehringer Ingelheim, Chugai, Novartis, Pfizer, Roche, Takeda. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.